Fine Tuning Mesenchymal Stromal Cells - Code For Mitigating Kidney Diseases

Stem Cell Rev Rep. 2024 Apr;20(3):738-754. doi: 10.1007/s12015-024-10684-9. Epub 2024 Feb 9.

Abstract

Kidney Disease (KD), has a high global prevalence and accounts for one of the most prominent causes of morbidity and mortality in the twenty-first century. Despite the advances in our understanding of its pathophysiology, the only available therapy options are dialysis and kidney transplantation. Mesenchymal stem cells (MSCs) have proven to be a viable choice for KD therapy due to their antiapoptotic, immunomodulatory, antioxidative, and pro-angiogenic activities. However, the low engraftment, low survival rate, diminished paracrine ability, and delayed delivery of MSCs are the major causes of the low clinical efficacy. A number of preconditioning regimens are being tested to increase the therapeutic capabilities of MSCs. In this review, we highlight the various strategies to prime MSCs and their protective effects in kidney diseases.

Keywords: Anti fibrotic; Immune modulation; Kidney Disease; Mesenchymal Stromal Cells; Preconditioning.

Publication types

  • Review

MeSH terms

  • Immunomodulation
  • Mesenchymal Stem Cells* / physiology